Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-p2v8j Total loading time: 0 Render date: 2024-06-08T10:06:10.791Z Has data issue: false hasContentIssue false

56 - Cervical cancer

from Part 3.1 - Molecular pathology: carcinomas

Published online by Cambridge University Press:  05 February 2015

John Doorbar
Affiliation:
Division of Virology, National Institute for Medical Research, London, UK
Edward P. Gelmann
Affiliation:
Columbia University, New York
Charles L. Sawyers
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Frank J. Rauscher, III
Affiliation:
The Wistar Institute Cancer Centre, Philadelphia
Get access

Summary

Cervical cancer encompasses both squamous-cell carcinoma and adenocarcinoma, which are thought to have different cellular origins (1–3). Unlike most cancers, the development of cervical cancer is intrinsically linked to infection by a very common virus (4,5). This is the human papillomavirus (HPV), which is a small non-enveloped icosohedral particle containing a double-stranded circle (or episome) of DNA (6). Papillomaviruses typically contain around 8000 base pairs of DNA and usually encode eight or nine open reading frames (or genes) and with these they complete their productive life cycle in the epithelium or cause neoplasia and possibly cancer (3,7). At the outset, there are two very important points to note regarding these viruses. The first is that although there are a large number of different papillomavirus types that infect humans, only a small subset (known as the “high-risk” types) cause lesions which progress to cancer (4,8). These viruses, like all papillomaviruses, are prevalent in the general population, which leads us to the second point. Only a small fraction of these high-risk papillomavirus infections will progress to cancer (8,9). Most will be cleared by the body's immune system over a period of months or years. Thus the development of cervical cancer is associated with persistent infection by a high-risk HPV type. In fact, this is not quite the whole story, as HPV-associated cancers develop primarily at certain sites of the body, and the most important of these is the cervical transformation zone, although other transformation zone sites are also vulnerable, such as the anal transformation zone (2,3). These are particular sites where viral gene expression is not always properly regulated and where the expression of viral genes can, over time, facilitate the accumulation of genetic errors in the infected cell that can ultimately lead to cancer.

Type
Chapter
Information
Molecular Oncology
Causes of Cancer and Targets for Treatment
, pp. 630 - 640
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schiffman, M, Wentzensen, N, Wacholder, S, et al. Human papillomavirus testing in the prevention of cervical cancer. Journal of the National Cancer Institute 2011;103:368–83.CrossRefGoogle ScholarPubMed
Jenkins, D. Histopathology and cytopathology of cervical cancer. Disease Markers 2007;23:199–212.CrossRef
Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science (London) 2006;110:525–41.CrossRef
zur Hausen, H. Papillomaviruses in the causation of human cancers: a brief historical account. Virology 2009;384:260–5.CrossRef
Walboomers, JM, Jacobs, MV, Manos, MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 1999;189: 12–19.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Doorbar, J. The papillomavirus life cycle. Journal of Clinical Virology 2005;32: 7–15.CrossRefGoogle ScholarPubMed
Moody, CA, Laimins, LA. Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer 2010;10: 550–60.CrossRef
Bosch, FX, Burchell, AN, Schiffman, M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26: K1–16.
Schiffman, M, Castle, PE, Jeronimo, J, Rodriguez, AC, Wacholder, S. Human papillomavirus and cervical cancer. Lancet 2007;370: 890–907.CrossRef
Shah, SD, Doorbar, J, Goldstein, RA. Analysis of host-parasite incongruence in papillomavirus evolution using importance sampling. Molecular Biology and Evolution 2010;27:1301–14.CrossRef
Schiffman, M, Herrero, R, Desalle, R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76–84.CrossRef
Gottschling, M, Göker, M, Stamatakis, A, et al. Quantifying the phylodynamic forces driving papillomavirus evolution. Molecular Biology and Evolution 2011;28:2101–13.CrossRef
Bernard, HU, Buek, RD, Chen, Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70–9.CrossRef
Van Doorslaer, K, Bernard, HU, Chen, Z, et al. Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends in Microbiology 2011;19:49–50; author reply 50–1.
de Villiers, EM, Fauquet, C, Broker, TR, Bernard, HU, zur Hausen, H. Classification of papillomaviruses. Virology 2004;324:17–27.CrossRef
Dubina, M, Goldenberg, G. Viral-associated nonmelanoma skin cancers: a review. American Journal of Dermatopathology 2009; 31:561–73.CrossRefGoogle ScholarPubMed
Gewirtzman, A, Bartlett, B, Tyring, S. Epidermodysplasia verruciformis and human papilloma virus. Current Opinion in Infectious Diseases 2008;21:141–6.CrossRef
Lebwohl, MG, Rosen, T, Stockfleth, E. The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic options. Cutis;86:suppl 1–11;quiz suppl 12.
Hsueh, PR. Human papillomavirus, genital warts, and vaccines. Journal of Microbiology, Immunology and Infection 2009;42:101–6.Google ScholarPubMed
Donne, AJ, Clarke, R. Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children. International Journal of STD and AIDS 2010;21:381–5.CrossRefGoogle ScholarPubMed
Baseman, JG, Koutsky, LA. The epidemiology of human papillomavirus infections. Journal of Clinical Virology 2005;32:S16–24.CrossRefGoogle ScholarPubMed
Stanley, M. Immune responses to human papillomavirus. Vaccine 2006;24:S16–22.
Ashrafi, GH, Haghshenas, M, Marchetti, B, Campo, MS. E5 protein of human papillomavirus 16 down-regulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. International Journal of Cancer 2006;119:2105–12.CrossRefGoogle Scholar
Li, S, Labrecque, S, Gauzzi, MC, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999;18:5727–37.CrossRef
Zhou, F, Leggatt, GR, Frazer, IH. Human papillomavirus 16 E7 protein inhibits interferon-gamma-mediated enhancement of keratinocyte antigen processing and T-cell lysis. FEBS Journal 2011;278:955–63.CrossRef
Hebner, C, Beglin, M, Laimins, LA. Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. Journal of Virology 2007;81:12 740–7.CrossRefGoogle ScholarPubMed
Kines, RC, Thompson, CD, Lowy, DR, Schiller, JT, Day, PM. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proceedings of the National Academy of Sciences USA 2009;106:20 458–63.
Schiller, JT, Day, PM, Kines, RC. Current understanding of the mechanism of HPV infection. Gynecologic Oncology 2010;118:S12–17.
Fuchs, E, Nowak, JA. Building epithelial tissues from skin stem cells. Cold Spring Harbor Symposia on Quantitative Biology 2008;73:333–50.CrossRef
Doorbar, J, Cubie, H. Molecular basis for advances in cervical screening. Molecuar Diagnosis 2005;9:129–42.CrossRef
Ghittoni, R, Accardi, R, Hasan, U, et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2009;40:1–13.CrossRef
Gariglio, P, Gutiérrez, J, Cortés, E, Vásuez, J. The role of retinoid deficiency and estrogens as cofactors in cervical cancer. Archives of Medical Research 2009;40:449–65.CrossRef
Ding, DC, Chiang, MH, Lai, HC, et al. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. European Journal of Obstetrics, Gynecology and Reproductive Biology 2009;147:215–20.CrossRefGoogle Scholar
Yu, T, Ferber, MJ, Cheung, TH, et al. The role of viral integration in the development of cervical cancer. Cancer Genetics and Cytogenetics 2005;158:27–34.CrossRef
Wentzensen, N, Ridder, R, Klaes, R, et al. Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. Oncogene 2002;21:419–26.CrossRef
Melsheimer, P, Vinokurova, S, Wentzensen, N, Bastert, G, van Knebel Doeberitz, M. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clinical Cancer Research 2004;10:3059–63.CrossRef
Vinokurova, S, Wentzensen, N, Kraus, I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Research 2008;68:307–13.CrossRef
Pett, M, Coleman, N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?Journal of Pathology 2007;212:356–67.CrossRefGoogle ScholarPubMed
Barrow-Laing, L, Chen, W, Roman, A. Low- and high-risk human papillomavirus E7 proteins regulate p130 differently. Virology 2010;400:233–9.CrossRef
Zhang, B, Chen, W, Roman, A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proceedings of the National Academy of Sciences USA 2006;103:437–42.CrossRef
Wang, SS, Trunk, M, Schiffman, M, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiology Biomarkers and Prevention 2004;13:1355–60.
Howie, HL, Katzenellenbogen, RA, Galloway, DA. Papillomavirus E6 proteins. Virology 2009;384:324–34.CrossRef
Lepik, D, Ilves, I, Kristjuhan, A, Maimets, T, Ustav, M. p53 protein is a suppressor of papillomavirus DNA amplificational replication. Journal of Virology 1998;72:6822–31.Google ScholarPubMed
Hidalgo, A, Baudis, M, Petersen, I, et al. Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 2005;5:77.CrossRef
Zhang, A, Måér, S, Betz, R, et al. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. International Journal of Cancer 2002;101:427–33.CrossRefGoogle ScholarPubMed
Mahmud, SM, Robinson, K, Richardson, H, et al. HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. Journal of Infectious Diseases 2007;196:82–90.CrossRefGoogle Scholar
Maciag, PC, Schlecht, NF, Souza, PS, et al. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiology Biomarkers and Prevention 2000;9:1183–91.
Lucey, BP, Nelson-Rees, WA, Hutchins, GM. Henrietta Lacks, HeLa cells, and cell culture contamination. Archives of Pathology and Laboratory Medicine 2009;133:1463–7.
Goodwin, EC, DiMaio, D. Induced senescence in HeLa cervical carcinoma cells containing elevated telomerase activity and extended telomeres. Cell Growth and Differentiation 2001;12:525–34.
Desaintes, C, Demeret, C, Goyat, S, Yaniv, M, Thierry, F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO Journal 1997;16:504–14.CrossRef
Wilting, SM, Steenbergen, RD, Tijssen, M, et al. Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. Cancer Research 2009;69:647–55.CrossRef
Umayahara, K, Numa, F, Suehiro, Y, et al. Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes, Chromosomes and Cancer 2002;33:98–102.CrossRef
Bierkens, M, Wilting, SM, van Wieringen, WN, et al. Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. International Journal of Cancer 2012;131:E579–85.CrossRefGoogle ScholarPubMed
Heselmeyer, K, Schröck, E, du Manoir, S, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proceedings of the National Academy of Sciences of the United States of America 1996;93:479–84.CrossRef
Wilting, SM, de Wilde, J, Meijer, CJ, et al. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes, Chromosomes and Cancer 2008;47:890–905.CrossRef
Herfs, M, Yamamoto, Y, Laury, A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proceedings of the National Academy of Sciences of the United States of America 2012;109:10 516–21.
Schiffman, M, Rodriguez, AC, Chen, Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Research 2010;70:3159–69.CrossRef
Koshiol, JE, Schroeder, JC, Jamieson, DJ, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. International Journal of Cancer 2006;119:1623–9.CrossRefGoogle ScholarPubMed
Nees, M, Geoghegan, JM, Hyman, T, et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. Journal of Virology 2001;75:4283–96.CrossRefGoogle ScholarPubMed
Perea, SE, Massimi, P, Banks, L. Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. International Journal of Molecular Medicne 2000;5:661–6.Google ScholarPubMed
Um, SJ, Rhyu, JW, Kim, EJ, et al. Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Letters 2002;179:205–12.CrossRef
Caberg, JH, Hubert, PM, Begon, DY, et al. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. Carcinogenesis 2008;29:1441–7.CrossRef
Matthews, K, Leong, CM, Baxter, L, et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. Journal of Virology 2003;77:8378–85.CrossRefGoogle ScholarPubMed
Welters, MJ, de Jong, A, van den Eeden, SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Research 2003;63:636–41.
de Jong, A, van Poelgeest, MI, van der Hulst, JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Research 2004;64:5449–55.CrossRef
Ades, S, Koushik, A, Duarte-Franco, E, et al. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. International Journal of Cancer 2008;122:2820–6.CrossRefGoogle Scholar
Sheu, BC, Chiou, SH, Chang, WC, et al. Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma. Clinical Immunology 2005;115:295–301.CrossRef
Zoodsma, M, Nolte, IM, Te Meerman, GJ, De Vries, EG, Van der Zee, AG. HLA genes and other candidate genes involved in susceptibility for (pre)neoplastic cervical disease. International Journal of Oncology 2005;26:769–84.Google ScholarPubMed
Stampler, KM, Dunton, CJ. Cervical neoplasia guidelines: United States and Europe compared. Journal of Lower Genital Tract Disease 2010;14:142–7.CrossRefGoogle ScholarPubMed
Armarnik, S, Sheiner, E, Piura, B, et al. Obstetric outcome following cervical conization. Archives of Gynecology and Obstetrics 2011;283:765–9.CrossRef
Ortoft, G, Henriksen, T, Hansen, E, Patersen, L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. British Journal of Obstetrics and Gynecology 2011;117:258–67.CrossRefGoogle Scholar
Peto, J, Gilham, C, Fletcher, O, Matthews, FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249–56.CrossRef
Cuzick, J, Arbyn, M, Sankaranarayanan, R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26:K29–41.
Arbyn, M, Castellsagué, X, de Sanjosé, S, et al. Worldwide burden of cervical cancer in 2008. Annals of Oncology 2011;22:2675–86.CrossRef
Meijer, CJ, Berkhof, H, Heideman, DA, Hesselink, AT, Snijders, PJ. Validation of high-risk HPV tests for primary cervical screening. Journal of Clinical Virology 2009;46:S1–4.CrossRefGoogle ScholarPubMed
Doorbar, JC, Cubie, H. Molecular basis for advances in cervical screening. Molecular Diagnostics 2005;9:129–42.
Stanley, M, Gissmann, L, Nardelli-Haefliger, D. Immunobiology of human papillomavirus infection and vaccination: implications for second generation vaccines. Vaccine 2008;26:K62–7.
Kwak, K, Yemelyanova, A, Roden, RB. Prevention of cancer by prophylactic human papillomavirus vaccines. Current Opinion in Immunology 2011;23:244–51.CrossRef
Kubba, T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reproductive Health Matters 2008;16:97–103.
Miller, RL, Meng, TC, Tomai, MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspectives 2008;21:69–87.CrossRef
Doorbar, J, Griffin, H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opinion in Biological Therapy 2007;7:677–89.CrossRef
Butz, K, Ristriani, T, Hengstermann, A, et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003;22:5938–45.CrossRef
van der Burg, SH, Melief, CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Current Opinion in Immunology 2011;23:252–7.CrossRef
Kenter, GG, Welters, MJ, Valentijn, AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New England Journal of Medicine 2009;361:1838–47.CrossRefGoogle ScholarPubMed
Muñoz, N, Bosch, FX, Castellsagué, X, et al. Against which human papillomavirus types shall we vaccinate and screen?: the international perspective. International Journal of Cancer 2004;111:278–85.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×